{
    "clinical_study": {
        "@rank": "127603", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "PD 0332991 will be given orally days 1,2,3\nCytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6\nMitoxantrone will be given over 2 hour infusion  day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
        }, 
        "brief_summary": {
            "textblock": "1.1 Primary Objectives\n\n        -  To determine the feasibility, tolerability, and toxicities of administering the\n           selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and\n           Mitoxantrone for adults with relapsed and refractory acute leukemias and high risk\n           myelodysplasias (MDS), including primary refractory disease\n\n        -  To determine the direct cytotoxic effects of single agent PD 0332991 on malignant\n           blasts\n\n        -  To determine the maximal tolerated dose (MTD) of PD 0332991 in timed sequential\n           combination with ara-C and Mitoxantrone\n\n        -  To determine if the timed sequential combination of PD 0332991 with ara-C and\n           mitoxantrone can induce clinical responses in adults with relapsed or refractory acute\n                     leukemias and high-risk MDS\n\n      1.2 Secondary Objectives:\n\n        -  To determine the ability of PD 0332991 to directly induce apoptosis in malignant cell\n           populations in vivo\n\n        -  To obtain pharmacodynamic (PD) data regarding the ability of PD 0332991 to arrest\n           malignant cells in the G 1 phase of cell cycle, followed by synchronized release of\n           those cells into S phase upon discontinuation of PD 0332991 and resultant enhanced\n           ara-C cytotoxicity"
        }, 
        "brief_title": "A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "PD 0332991 will be given orally days 1,2,3\nCytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6\nMitoxantrone will be given over 2 hour infusion  day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose", 
                        "title": "Arm 1"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "2"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "27", 
                                            "@value": "45.5"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "2"
                                        }
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "All Principal Investigators ARE employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The number of participants experiencing toxicities of administration of PD 0332991 in combination with cytarabine and mitoxantrone will be measured according to NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "PD 0332991 will be given orally days 1,2,3\nCytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6\nMitoxantrone will be given over 2 hour infusion  day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose", 
                                "title": "Arm 1"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "2"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "2"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The number of participants experiencing toxicities of administration of PD 0332991 in combination with cytarabine and mitoxantrone will be measured according to NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                                    "param": "Number", 
                                    "title": "The Toxicities of Administration of PD 0332991 in Combination With Cytarabine and Mitoxantrone.", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "42 days", 
                        "title": "The Toxicities of Administration of PD 0332991 in Combination With Cytarabine and Mitoxantrone.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Dose escalation decisions will be based on nonhematologic toxicities in Cycle 1 (28 days) and hematologic toxicities, in the case of an aplastic marrow through Day 56, For cytopenias including ANC < 500/mm3 or platelets < 50, 000/mm3 a bone marrow will be performed between days 42 and 49.. Dose limiting toxicity (DLT) will be measured according to NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                        "safety_issue": "Yes", 
                        "time_frame": "42 days", 
                        "title": "To Determine the Maximal Tolerated Dose (MTD) of PD 0332991 in Timed Sequential Combination With Ara-C and Mitoxantrone", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "PD 0332991 125 was given orally days 1,2,3\nCytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6\nMitoxantrone will be given over 2 hour infusion  day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose", 
                        "title": "Arm 1"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "2 subjects were accrued"
            }, 
            "point_of_contact": {
                "email": "Igojo1@jhmi.edu", 
                "name_or_title": "Ivana Gojo, MD", 
                "organization": "Johns Hopkins University", 
                "phone": "410-502-7726"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "PD 0332991 will be given orally days 1,2,3\nCytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6\nMitoxantrone will be given over 2 hour infusion  day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose", 
                        "title": "Arm 1"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "2"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "2", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "2"
                                        }, 
                                        "sub_title": {
                                            "#text": "mucositis", 
                                            "@vocab": "10034835"
                                        }
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "CTCAE (4.0)", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "2"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "2"
                                        }, 
                                        "sub_title": {
                                            "#text": "Bone marrow aplasia", 
                                            "@vocab": "10048580"
                                        }
                                    }
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "2"
                                        }, 
                                        "sub_title": {
                                            "#text": "Hyperbilirubinemia", 
                                            "@vocab": "10005364"
                                        }
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "CTCAE (4.0)"
                }
            }
        }, 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Relapsed Acute Leukemia", 
            "Refractory Acute Leukemia", 
            "High-Risk Myelodysplasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults age \u2265 18 years\n\n               -  Multilineage bone marrow failure\n\n               -  Serum creatinine \u2264 2.0 mg/dl\n\n               -  Hepatic enzymes (AST, ALT) \u2264 3x upper limit of normal (ULN)\n\n               -  Bilirubin \u2264 2.0 mg/dl, unless due to Gilbert's disease, hemolysis or leukemic\n                  infiltration\n\n               -  Left ventricular ejection fraction \u2265 45%\n\n               -  QTc \u2264 470 msec\n\n               -  RB expression is required for the action of PD 0332991. Because rb deletions and\n                  mutations are rare in acute leukemias and MDS, screening for RB expression will\n                  not be required before enrollment. Pretreatment biopsies will be stored and\n                  analyzed for RB expression if needed subsequently.\n\n        Exclusion Criteria:\n\n          -  \u2022 No more than 5 cytotoxic regimens\n\n               -  Previous allogeneic or autologous stem cell transplantation permitted\n\n               -  \u2265 3 weeks delay from prior cytotoxic chemotherapy or radiation therapy\n\n               -  \u2265 2 week delay from prior biologic therapies including hematopoietic growth\n                  factors and vidaza or decitabine\n\n               -  If using Hydroxyurea, steroids, tyrosine kinase/src kinase inhibitors, arsenic,\n                  interferon for count control, must be off therapy for \u2265 48 hours prior to\n                  beginning PD 0332991\n\n               -  No concomitant use of potent CYP450 3A4 inhibitors (e.g. triazole antifungal\n                  agents) or inducers (e.g. omperazole, dilantin, dexamethasone) within 7 days\n                  prior to beginning PD 0332991"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "firstreceived_results_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701375", 
            "org_study_id": "J1275", 
            "secondary_id": "NA_00076003"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "description": "\u2022\tPD 0332991 will be given orally days 1,2,3", 
            "intervention_name": "PD 0332991", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Mitoxantrone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weill Cornell Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias", 
        "overall_official": {
            "affiliation": "Sidney Kimmel Comprehensive Cancer Center", 
            "last_name": "Judith Karp, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The number of participants experiencing toxicities of administration of PD 0332991 in combination with cytarabine and mitoxantrone will be measured according to NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "measure": "The Toxicities of Administration of PD 0332991 in Combination With Cytarabine and Mitoxantrone.", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701375"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Dose escalation decisions will be based on nonhematologic toxicities in Cycle 1 (28 days) and hematologic toxicities, in the case of an aplastic marrow through Day 56, For cytopenias including ANC < 500/mm3 or platelets < 50, 000/mm3 a bone marrow will be performed between days 42 and 49.. Dose limiting toxicity (DLT) will be measured according to NCI-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "measure": "To Determine the Maximal Tolerated Dose (MTD) of PD 0332991 in Timed Sequential Combination With Ara-C and Mitoxantrone", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Leukemia and Lymphoma Society", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pfizer", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Material sponsor withdrew support"
    }
}